contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious … correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first …

; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration … contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious …

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious … correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first …

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious … correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first …

; Innovation ; Pharmaceuticals ; Health care expenditure ; Cointegration … contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious …

Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at … pharmaceutical innovation increased mean age at death by 0.87 years (10.4 months) - about 44% of the total increase in longevity … pharmaceutical innovation. The baseline estimate of the cost per life-year gained from pharmaceutical innovation in Greece is $17 …

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious … correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

contribution by Lichtenberg (2004), which relates longevity in the United States to pharmaceutical innovation and public health …In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious … correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first …